AbbVie Inc.

Good morning and thank you for standing by. Welcome to the ABBE third quarter 2024 earnings conference call. All participants will be able to listen only until the question and answer portion of this call. You may ask a question by pressing star 1 on your phone. Today's call is being recorded. I would now like to introduce Ms. Liz Shea, Senior Vice President, Investor Relations.

Good morning and thanks for joining us. Also on the call with me today are Rob Michael, Chief Executive Officer, Jeff Stewart, Executive Vice President, Chief Commercial Officer, Rupal Thakkar, Executive Vice President, Research and Development, Chief Scientific Officer, Scott Renz, Executive Vice President, Chief Financial Officer, and Kerry Strom, Senior Vice President, APPE, and President, Global Allergan Aesthetics. Before we get started, I'll note that some statements we make today may be considered forward-looking statements based on our current expectations. Abby cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in our forward-looking statements. Additional information about these risks and uncertainties is included in our SEC filings. Abby undertakes no obligation to update these forward-looking statements except as required by law. On today's conference call, non-GAAP financial measures will be used to help investors understand Abby's business performance These non-GAAP financial measures are reconciled with comparable GAAP financial measures in our earnings release and regulatory filings from today, which can be found on our website. Following our prepared remarks, we'll take your questions. So with that, I'll turn the call over to Rob.

Thank you, Liz. Good morning, everyone, and thank you for joining us. AbbVie is performing exceptionally well, and I'm extremely pleased with the execution against our strategic priorities, including... continued double-digit sales growth from our ex-Humera platform, the closing and integration of Cereval Therapeutics, and the progress we are making to build and advance a compelling pipeline of innovative medicines. Turning to our results, AVI's diversified portfolio delivered sales that were $260 million above our expectations and reflect robust mid-single-digit operational sales growth. Our Exumair platform drove this overachievement, including growth of nearly 18%. The momentum of Skyrizzy and Renvoke is especially impressive, with combined sales expected to exceed $17 billion this year, which is $1.3 billion above our initial expectations. And we see substantial opportunity for continued strong growth well into the next decade. Several other key products also delivered double-digit sales growth, including Benklexta, Vralar, Ubrelvi, and Qlypta. This broad-based performance further demonstrates the strength of our commercial portfolio. For the third time this year, we are raising our full-year revenue and adjusted EPS guidance. We are increasing our full-year revenue guidance by $500 million. and have now raised total revenue by $1.8 billion since our initial guidance in February. We are also raising our full-year adjusted earnings per share guidance by $0.15 and now expect adjusted EPS between $10.90 and $10.94. In addition to achieving strong quarterly results, we have been very focused on investing in the business to generate sustainable long-term performance in the 2030s and beyond. During the quarter, we successfully completed the acquisition of Cereval Therapeutics, strengthening our neuroscience pipeline. Cereval enhances our ability to help patients suffering from devastating conditions, such as Parkinson's and schizophrenia. The integration has been seamless, and we are excited to have the talented Cereval team join our organization. Within the Cereval pipeline, we are very pleased with the positive phase three results and emerging profile of Tevapidon in Parkinson's, and we remain on track to read out both pivotal studies for Imraclidine and schizophrenia in the fourth quarter. More broadly on the pipeline, we have been advancing key R&D programs across all stages of development. Some notable highlights include the U.S. approvals of Violev for advanced Parkinson's and Botox for platysma bands, the U.S. regulatory submission of Teliso-V for non-squamous, non-small cell lung cancer, and the start of our Phase II Crohn's platform study. which is evaluating Sky RISI in combination with several novel biologics. In summary, AVI continues to demonstrate strong commercial, operational, and R&D execution. The robust performance of our growth platform once again exceeded our expectations, and we see numerous opportunities to drive long-term growth. Further underscoring our confidence in that growth Today we announced a 5.8% increase in our quarterly cash dividend, beginning with the dividend payable in February 2025. Since inception, we have increased our quarterly dividend by more than 300%. With that, I'll turn the call over to Jeff for additional comments on our commercial highlights. Jeff?